November 27 - Yunnan Walvax Biotech Co., Ltd. announced that its 13-valent pneumococcal polysaccharide conjugate vaccine has recently obtained the "Biological Product Marketing Authorization" issued by the Egyptian Drug Authority (EDA), signifying the vaccine's official approval for marketing in Egypt.

Deng Zhidong, General Manager of Hainan Boao Medical Technology Co., Ltd., stated to Securities Daily that in recent years, several Chinese vaccine enterprises have leveraged their advantages of "high quality, cost-effectiveness, and flexibility" to effectively seize overseas market opportunities. Through diverse approaches such as exporting finished vaccines and providing localized production support, they are ensuring vaccine supply security in low-income countries and regions lacking independent production or procurement capabilities.

According to the reporter's research, recently multiple listed vaccine companies have announced new progress in their overseas market expansion, indicating an acceleration of their globalization strategies.

On November 24, Beijing Sinovac Holdings (Group) Co., Ltd. signed two Product Development Partnership (PDP) project agreements with the Brazilian Ministry of Health. This achievement made Sinovac the first Chinese vaccine manufacturer to win a core public health project of this nature in Brazil, securing a decade-long vaccine cooperation order valued at over USD 700 million.

As of October 2025, the bivalent HPV vaccine produced by Xiamen Innovac Co., Ltd. (hereinafter referred to as "Innovac") has been marketed in countries including Angola, Pakistan, and Belarus. Notably, sales of this vaccine in Thailand have surpassed 2 million doses.

Liaoning Chengda Biotechnology Co., Ltd. (hereinafter referred to as "Chengda Biotech") has expanded its human rabies vaccine business to over 30 countries. In the first half of this year, it gained market access in Indonesia and is actively exploring markets including Brazil, steadily advancing its vaccine "going global" strategy and continuously strengthening its international market presence.

Recently, Walvax Biotech has achieved significant progress in overseas market expansion. The company's 13-valent pneumococcal conjugate vaccine has newly entered markets in Chile and Jordan, while its 23-valent pneumococcal polysaccharide vaccine has newly entered markets in Chile, Mexico, and El Salvador. Additionally, the local production project for its 13-valent pneumococcal conjugate vaccine in Indonesia has been completed, and the company has begun exporting bulk drug substances to its local partner.

A representative of Walvax Biotech stated to Securities Daily: "The company's vaccine products have been exported to more than 24 countries and regions cumulatively, with export volumes exceeding 63 million doses. Walvax will continue to promote the penetration of its marketed products in the domestic market and the expansion of the international market, benefiting more people overseas with innovative vaccines based on the 'Chinese technology - local production' model."

With the expansion into overseas markets, several vaccine companies have also achieved steady growth in overseas sales revenue, making it a "new engine" for their performance growth.

For example, in the first half of this year, Chengda Biotech recorded overseas sales revenue of RMB 123 million, a year-on-year increase of 26.96%; Innovac's vaccine business achieved overseas sales revenue of RMB 64.6741 million, a year-on-year increase of 77.51%. In the first three quarters of this year, Shenzhen Kangtai Biological Products Co., Ltd. generated overseas revenue of RMB 41.8956 million, a year-on-year increase of 324.27%.

Xu Wen, pharmaceutical industry analyst at Xiangcai Securities, stated that the vaccine industry is currently in a transitional phase from scale expansion to innovation-driven development. While supply-demand imbalances and homogeneous competition are causing short-term industry pains, the long-term positive outlook remains unchanged, with policy, demand, and technology being the three key drivers of industry development.

From product exports to localized technology cooperation, Chinese vaccine companies are exploring diversified "going global" pathways. The aforementioned Walvax representative stated: "The company will strengthen communication and cooperation with global health organizations and overseas biopharmaceutical companies, adopt diversified models, continuously deepen product registration and exports in overseas markets, and maintain the high-quality development trend of its overseas business."